About this trial

The purpose of this study is to identify genes that increase the risk of developing vasculitis, a group of severe diseases that feature inflammation of blood vessels. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies, and will be of great interest to the larger communities of researchers investigating vasculitis and other autoimmune, inflammatory, and vascular diseases.

Eligibility criteria

Qualifiers

New onset or new type of localized pain in the head

Temporal artery abnormality (i.e. temporal artery tenderness to palpation or decreased pulsation, unrelated to arteriosclerosis of cervical arteries)

ESR of >40mm in the first hour by the Westergren method

Abnormal artery biopsy (i.e. temporal artery biopsy showing vasculitis characterized by a predominance of mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant cells)

Disqualifiers

Inability to give informed consent and to sign the consent form

Enrolled in VCRC protocols 5502, 5503, 5504, 5505, 5506, 5522, or 5523

Unwilling to provide blood for DNA collection

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

14
Canada
St. Joseph's Healthcare HamiltonOntario, Canada
Mount Sinai HospitalM5T 3L9, TorontoOntario, Canada
Turkey (Türkiye)
Istanbul University34452, IstanbulFatih, Turkey (Türkiye)
United States
California
Cedars-Sinai Medical Center90048, Los Angeles United States

Sponsors and collaborators

University of Pennsylvania

Lead sponsor

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Collaborator

Office of Rare Diseases (ORD)

Collaborator

Rare Diseases Clinical Research Network

Collaborator